To discover whether disease-modifying anti-rheumatic drugs (DMARDs) influence the effectiveness of hormonal treatments, subsequent ablative surgery, and demand for pain management, involving non-steroidal anti-inflammatory drugs, anti-depressants, and opioids in females with endometriosis.
Endometriosis is a gynecologic condition that affects approximately
5–15% women of reproductive age in the USA. Number of previous studies reported
the use of disease-modifying anti-rheumatic drugs (DMARDs) against
endometriosis, but none of them showed the significant result. Therefore the
findings of this retrospective study suggest that administration of DMARDs for
at least six weeks is associated with decreased opioid usage among women with
endometriosis.
To discover whether disease-modifying anti-rheumatic
drugs (DMARDs) influence the effectiveness of hormonal treatments, subsequent
ablative surgery, and demand for pain management, involving non-steroidal
anti-inflammatory drugs, anti-depressants, and opioids in females with
endometriosis.
Females with surgically verified endometriosis who were
not treated or treated with DMARDs for six weeks or more prior to surgical
diagnosis between 2003 and 2013 at a single healthcare system in the USA were
reviewed to retrieve the data. Both groups were compared for postoperative use
of hormonal treatments, the performance of adjunct therapies such as steroids,
opioids, and antidepressants prior to the surgery, and the proportion of
females going through subsequent ablative surgery.
A difference in follow-up time and age was seen between
the groups. The females treated with DMARDs required more antidepressants and hormonal
treatments. The incidence of the post-diagnostic utility of opioids was reduced
in the treated females; this relationship remained vital in multivariate
analysis.
The outcomes recommend that introduction of DMARDs for at
least 6 weeks is linked with reduced opioid usage in the females with
endometriosis.
Int J Gynaecol Obstet. 2017 Dec 4
Effect of disease-modifying anti-rheumatic drugs on therapeutic outcomes among women with endometriosis
Kotlyar A et al.
Comments (0)